A phase 1b pharmacokinetic-pharmacodynamic-pharmacogenomic study of enzastaurin in patients with B-cell chronic lymphocytic leukemia (B-CLL)
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2013
At a glance
- Drugs Enzastaurin (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- Sponsors Eli Lilly
- 22 Nov 2013
- 24 Mar 2009 Actual patient number (18) added as reported by ClinicalTrials.gov.
- 24 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.